Loading…

Reassessing Breast Cancer-Associated Fibroblasts

Breast cancer (BC) is primarily classified by immunohistochemistry (IHC) and digital image analysis (DIA) based on distinct immunophenotypes of malignant epithelial cells. When antiangiogenic and immunomodulatory therapies are used for BC, the stromal components such as tumor vessels and immune cell...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-07, Vol.15 (15)
Main Authors: Barb, Alina Cristina, Fenesan, Mihaela Pasca, Pirtea, Marilena, Margan, Mădălin-Marius, Tomescu, Larisa, Ceban, Emil, Cimpean, Anca Maria, Melnic, Eugen
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 15
container_start_page
container_title Cancers
container_volume 15
creator Barb, Alina Cristina
Fenesan, Mihaela Pasca
Pirtea, Marilena
Margan, Mădălin-Marius
Tomescu, Larisa
Ceban, Emil
Cimpean, Anca Maria
Melnic, Eugen
description Breast cancer (BC) is primarily classified by immunohistochemistry (IHC) and digital image analysis (DIA) based on distinct immunophenotypes of malignant epithelial cells. When antiangiogenic and immunomodulatory therapies are used for BC, the stromal components such as tumor vessels and immune cells have received more attention. Cancer-associated fibroblasts (CAFs) are extensively investigated, but measuring them in immunostained tissues and determining how they relate to clinical and pathological criteria is still difficult in BC. Our earlier research using CD34 and α-smooth muscle actin (αSMA) immunohistochemistry showed a decrease of CD34-positive CAFs and an increase of αSMA-positive CAFs inside the tumor stroma. This early basic microscopic finding gives us the intention to employ DIA to improve SMA-positive CAF quantification accuracy. Additional DIA processed data correlations to pathologic parameters, survival, invasion, and recurrence indicated substantial differences between BC molecular subtypes, suggesting a unique CD34- and αSMA-positive CAF impact for each subtype. Background: Breast cancer (BC) stroma has CD34- and αSMA-positive cancer-associated fibroblasts (CAFs) differently distributed. During malignant transformation, CD34-positive fibroblasts decrease while αSMA-positive CAFs increase. The prevalence of αSMA-positive CAFs in BC stroma makes microscopic examination difficult without digital image analysis processing (DIA). DIA was used to compare CD34- and αSMA-positive CAFs among breast cancer molecular subgroups. DIA-derived data were linked to age, survival, tumor stroma vessels, tertiary lymphoid structures (TLS), invasion, and recurrence. Methods: Double immunostaining for CD34 and αSMA showed different CAF distribution patterns in normal and BC tissues. Single CD34 immunohistochemistry on supplemental slides quantified tumor stroma CD34_CAFs. Digital image analysis (DIA) data on CAF density, intensity, stromal score, and H-score were correlated with clinico-pathologic factors. Results: CD34/αSMA CAF proportion was significantly related to age in Luminal A (LA), Luminal B (LB), and HER2 subtypes. CD34_CAF influence on survival, invasion, and recurrence of LA, LB-HER2, and TNBC subtypes was found to be significant. The CD34/αSMA-expressing CAFs exhibited a heterogeneous impact on stromal vasculature and TLS. Conclusion: BC stromal CD34_CAFs/αSMA_CAFs have an impact on survival, invasion, and recurrence differently between BC molecul
doi_str_mv 10.3390/cancers15153823
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A760514147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A760514147</galeid><sourcerecordid>A760514147</sourcerecordid><originalsourceid>FETCH-LOGICAL-g677-b777d4cef4d36fc98e882a9e7e5e054cf2df00862b34916b51c492e321750a0a3</originalsourceid><addsrcrecordid>eNptTE1Lw0AQXcSCpfbca8Bz6n5P9hiDtUJBkN7LZjMbVtIEMvn_uKiHHpw5zHvzPhjbCb5XyvHn4MeAMwkjjKqkumNryUGW1jp9f4Mf2Jboi-dRSoCFNeOf6ImQKI198TJnshTNT1lZE00h-QW74pDaeWqHLNIjW0U_EG7_7oadD6_n5liePt7em_pU9hagbAGg0wGj7pSNwVVYVdI7BDTIjQ5RdpHzyspWaSdsa0TQTqKSAgz33KsNe_qt7f2AlzTGaZl9uCYKlxosN0ILDdm1_8eVt8NrCtOIMeX_TeAbAptWAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Reassessing Breast Cancer-Associated Fibroblasts</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central</source><creator>Barb, Alina Cristina ; Fenesan, Mihaela Pasca ; Pirtea, Marilena ; Margan, Mădălin-Marius ; Tomescu, Larisa ; Ceban, Emil ; Cimpean, Anca Maria ; Melnic, Eugen</creator><creatorcontrib>Barb, Alina Cristina ; Fenesan, Mihaela Pasca ; Pirtea, Marilena ; Margan, Mădălin-Marius ; Tomescu, Larisa ; Ceban, Emil ; Cimpean, Anca Maria ; Melnic, Eugen</creatorcontrib><description>Breast cancer (BC) is primarily classified by immunohistochemistry (IHC) and digital image analysis (DIA) based on distinct immunophenotypes of malignant epithelial cells. When antiangiogenic and immunomodulatory therapies are used for BC, the stromal components such as tumor vessels and immune cells have received more attention. Cancer-associated fibroblasts (CAFs) are extensively investigated, but measuring them in immunostained tissues and determining how they relate to clinical and pathological criteria is still difficult in BC. Our earlier research using CD34 and α-smooth muscle actin (αSMA) immunohistochemistry showed a decrease of CD34-positive CAFs and an increase of αSMA-positive CAFs inside the tumor stroma. This early basic microscopic finding gives us the intention to employ DIA to improve SMA-positive CAF quantification accuracy. Additional DIA processed data correlations to pathologic parameters, survival, invasion, and recurrence indicated substantial differences between BC molecular subtypes, suggesting a unique CD34- and αSMA-positive CAF impact for each subtype. Background: Breast cancer (BC) stroma has CD34- and αSMA-positive cancer-associated fibroblasts (CAFs) differently distributed. During malignant transformation, CD34-positive fibroblasts decrease while αSMA-positive CAFs increase. The prevalence of αSMA-positive CAFs in BC stroma makes microscopic examination difficult without digital image analysis processing (DIA). DIA was used to compare CD34- and αSMA-positive CAFs among breast cancer molecular subgroups. DIA-derived data were linked to age, survival, tumor stroma vessels, tertiary lymphoid structures (TLS), invasion, and recurrence. Methods: Double immunostaining for CD34 and αSMA showed different CAF distribution patterns in normal and BC tissues. Single CD34 immunohistochemistry on supplemental slides quantified tumor stroma CD34_CAFs. Digital image analysis (DIA) data on CAF density, intensity, stromal score, and H-score were correlated with clinico-pathologic factors. Results: CD34/αSMA CAF proportion was significantly related to age in Luminal A (LA), Luminal B (LB), and HER2 subtypes. CD34_CAF influence on survival, invasion, and recurrence of LA, LB-HER2, and TNBC subtypes was found to be significant. The CD34/αSMA-expressing CAFs exhibited a heterogeneous impact on stromal vasculature and TLS. Conclusion: BC stromal CD34_CAFs/αSMA_CAFs have an impact on survival, invasion, and recurrence differently between BC molecular subtypes. The tumor stroma DIA assessment may have predictive potential to prognosis and long-term follow-up of patients with breast cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15153823</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Breast cancer ; Equipment and supplies ; Image processing ; Immunohistochemistry ; Muscle proteins</subject><ispartof>Cancers, 2023-07, Vol.15 (15)</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Barb, Alina Cristina</creatorcontrib><creatorcontrib>Fenesan, Mihaela Pasca</creatorcontrib><creatorcontrib>Pirtea, Marilena</creatorcontrib><creatorcontrib>Margan, Mădălin-Marius</creatorcontrib><creatorcontrib>Tomescu, Larisa</creatorcontrib><creatorcontrib>Ceban, Emil</creatorcontrib><creatorcontrib>Cimpean, Anca Maria</creatorcontrib><creatorcontrib>Melnic, Eugen</creatorcontrib><title>Reassessing Breast Cancer-Associated Fibroblasts</title><title>Cancers</title><description>Breast cancer (BC) is primarily classified by immunohistochemistry (IHC) and digital image analysis (DIA) based on distinct immunophenotypes of malignant epithelial cells. When antiangiogenic and immunomodulatory therapies are used for BC, the stromal components such as tumor vessels and immune cells have received more attention. Cancer-associated fibroblasts (CAFs) are extensively investigated, but measuring them in immunostained tissues and determining how they relate to clinical and pathological criteria is still difficult in BC. Our earlier research using CD34 and α-smooth muscle actin (αSMA) immunohistochemistry showed a decrease of CD34-positive CAFs and an increase of αSMA-positive CAFs inside the tumor stroma. This early basic microscopic finding gives us the intention to employ DIA to improve SMA-positive CAF quantification accuracy. Additional DIA processed data correlations to pathologic parameters, survival, invasion, and recurrence indicated substantial differences between BC molecular subtypes, suggesting a unique CD34- and αSMA-positive CAF impact for each subtype. Background: Breast cancer (BC) stroma has CD34- and αSMA-positive cancer-associated fibroblasts (CAFs) differently distributed. During malignant transformation, CD34-positive fibroblasts decrease while αSMA-positive CAFs increase. The prevalence of αSMA-positive CAFs in BC stroma makes microscopic examination difficult without digital image analysis processing (DIA). DIA was used to compare CD34- and αSMA-positive CAFs among breast cancer molecular subgroups. DIA-derived data were linked to age, survival, tumor stroma vessels, tertiary lymphoid structures (TLS), invasion, and recurrence. Methods: Double immunostaining for CD34 and αSMA showed different CAF distribution patterns in normal and BC tissues. Single CD34 immunohistochemistry on supplemental slides quantified tumor stroma CD34_CAFs. Digital image analysis (DIA) data on CAF density, intensity, stromal score, and H-score were correlated with clinico-pathologic factors. Results: CD34/αSMA CAF proportion was significantly related to age in Luminal A (LA), Luminal B (LB), and HER2 subtypes. CD34_CAF influence on survival, invasion, and recurrence of LA, LB-HER2, and TNBC subtypes was found to be significant. The CD34/αSMA-expressing CAFs exhibited a heterogeneous impact on stromal vasculature and TLS. Conclusion: BC stromal CD34_CAFs/αSMA_CAFs have an impact on survival, invasion, and recurrence differently between BC molecular subtypes. The tumor stroma DIA assessment may have predictive potential to prognosis and long-term follow-up of patients with breast cancer.</description><subject>Breast cancer</subject><subject>Equipment and supplies</subject><subject>Image processing</subject><subject>Immunohistochemistry</subject><subject>Muscle proteins</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptTE1Lw0AQXcSCpfbca8Bz6n5P9hiDtUJBkN7LZjMbVtIEMvn_uKiHHpw5zHvzPhjbCb5XyvHn4MeAMwkjjKqkumNryUGW1jp9f4Mf2Jboi-dRSoCFNeOf6ImQKI198TJnshTNT1lZE00h-QW74pDaeWqHLNIjW0U_EG7_7oadD6_n5liePt7em_pU9hagbAGg0wGj7pSNwVVYVdI7BDTIjQ5RdpHzyspWaSdsa0TQTqKSAgz33KsNe_qt7f2AlzTGaZl9uCYKlxosN0ILDdm1_8eVt8NrCtOIMeX_TeAbAptWAQ</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Barb, Alina Cristina</creator><creator>Fenesan, Mihaela Pasca</creator><creator>Pirtea, Marilena</creator><creator>Margan, Mădălin-Marius</creator><creator>Tomescu, Larisa</creator><creator>Ceban, Emil</creator><creator>Cimpean, Anca Maria</creator><creator>Melnic, Eugen</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20230701</creationdate><title>Reassessing Breast Cancer-Associated Fibroblasts</title><author>Barb, Alina Cristina ; Fenesan, Mihaela Pasca ; Pirtea, Marilena ; Margan, Mădălin-Marius ; Tomescu, Larisa ; Ceban, Emil ; Cimpean, Anca Maria ; Melnic, Eugen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g677-b777d4cef4d36fc98e882a9e7e5e054cf2df00862b34916b51c492e321750a0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Equipment and supplies</topic><topic>Image processing</topic><topic>Immunohistochemistry</topic><topic>Muscle proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barb, Alina Cristina</creatorcontrib><creatorcontrib>Fenesan, Mihaela Pasca</creatorcontrib><creatorcontrib>Pirtea, Marilena</creatorcontrib><creatorcontrib>Margan, Mădălin-Marius</creatorcontrib><creatorcontrib>Tomescu, Larisa</creatorcontrib><creatorcontrib>Ceban, Emil</creatorcontrib><creatorcontrib>Cimpean, Anca Maria</creatorcontrib><creatorcontrib>Melnic, Eugen</creatorcontrib><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barb, Alina Cristina</au><au>Fenesan, Mihaela Pasca</au><au>Pirtea, Marilena</au><au>Margan, Mădălin-Marius</au><au>Tomescu, Larisa</au><au>Ceban, Emil</au><au>Cimpean, Anca Maria</au><au>Melnic, Eugen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reassessing Breast Cancer-Associated Fibroblasts</atitle><jtitle>Cancers</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>15</volume><issue>15</issue><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Breast cancer (BC) is primarily classified by immunohistochemistry (IHC) and digital image analysis (DIA) based on distinct immunophenotypes of malignant epithelial cells. When antiangiogenic and immunomodulatory therapies are used for BC, the stromal components such as tumor vessels and immune cells have received more attention. Cancer-associated fibroblasts (CAFs) are extensively investigated, but measuring them in immunostained tissues and determining how they relate to clinical and pathological criteria is still difficult in BC. Our earlier research using CD34 and α-smooth muscle actin (αSMA) immunohistochemistry showed a decrease of CD34-positive CAFs and an increase of αSMA-positive CAFs inside the tumor stroma. This early basic microscopic finding gives us the intention to employ DIA to improve SMA-positive CAF quantification accuracy. Additional DIA processed data correlations to pathologic parameters, survival, invasion, and recurrence indicated substantial differences between BC molecular subtypes, suggesting a unique CD34- and αSMA-positive CAF impact for each subtype. Background: Breast cancer (BC) stroma has CD34- and αSMA-positive cancer-associated fibroblasts (CAFs) differently distributed. During malignant transformation, CD34-positive fibroblasts decrease while αSMA-positive CAFs increase. The prevalence of αSMA-positive CAFs in BC stroma makes microscopic examination difficult without digital image analysis processing (DIA). DIA was used to compare CD34- and αSMA-positive CAFs among breast cancer molecular subgroups. DIA-derived data were linked to age, survival, tumor stroma vessels, tertiary lymphoid structures (TLS), invasion, and recurrence. Methods: Double immunostaining for CD34 and αSMA showed different CAF distribution patterns in normal and BC tissues. Single CD34 immunohistochemistry on supplemental slides quantified tumor stroma CD34_CAFs. Digital image analysis (DIA) data on CAF density, intensity, stromal score, and H-score were correlated with clinico-pathologic factors. Results: CD34/αSMA CAF proportion was significantly related to age in Luminal A (LA), Luminal B (LB), and HER2 subtypes. CD34_CAF influence on survival, invasion, and recurrence of LA, LB-HER2, and TNBC subtypes was found to be significant. The CD34/αSMA-expressing CAFs exhibited a heterogeneous impact on stromal vasculature and TLS. Conclusion: BC stromal CD34_CAFs/αSMA_CAFs have an impact on survival, invasion, and recurrence differently between BC molecular subtypes. The tumor stroma DIA assessment may have predictive potential to prognosis and long-term follow-up of patients with breast cancer.</abstract><pub>MDPI AG</pub><doi>10.3390/cancers15153823</doi></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2023-07, Vol.15 (15)
issn 2072-6694
2072-6694
language eng
recordid cdi_gale_infotracmisc_A760514147
source Access via ProQuest (Open Access); PubMed Central
subjects Breast cancer
Equipment and supplies
Image processing
Immunohistochemistry
Muscle proteins
title Reassessing Breast Cancer-Associated Fibroblasts
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A41%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reassessing%20Breast%20Cancer-Associated%20Fibroblasts&rft.jtitle=Cancers&rft.au=Barb,%20Alina%20Cristina&rft.date=2023-07-01&rft.volume=15&rft.issue=15&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15153823&rft_dat=%3Cgale%3EA760514147%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g677-b777d4cef4d36fc98e882a9e7e5e054cf2df00862b34916b51c492e321750a0a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A760514147&rfr_iscdi=true